Oncolytic Adenovirus Service

Having a broad tissue tropism and the capability of infecting a large variety of dividing and non-dividing cells, adenoviruses belong to the most intensively studied viral vectors for gene therapy, and oncolysis. In addition to their potent lytic activity, adenoviruses have several striking advantages for pharmacologic application. The adenoviral genome is easily accessible for genetic manipulation and the well-understood adenovirus biology provides for ample opportunities of tailored gene modifications. With regard to manufacturing, adenoviruses can be produced at high titers and particles are of excellent physicochemical stability. Regarding safe clinical applicability, tumor-selective replication has been considered as an important precondition to prevent excess damage to non-target, healthy tissue. Early expressed viral proteins that are essentially involved in transformation of the cell have been considered as excellent targets for construction of tumor-selectively replicating adenoviruses.

Oncolytic adenoviruses selectively replicate in and lyse cancer cells and are therefore commonly used vectors in clinical trials for cancer gene therapy. Based on the well-characterized adenoviral natural tropism, genetic modification of oncolytic adenoviruses can enhance/regulate their transduction and replication within specific cancer cell types. However, oncolytic adenoviruses -mediated tumor cell lysis cannot fully eliminate tumors. The hostile tumor microenvironment provides a number of barriers to efficient oncolytic virotherapy, as tumors develop structure and immune-evasion mechanisms to grow and ultimately spread. For these reasons, oncolytic adenoviruses modified to deliver structural or immune modulatory molecules (Armed oncolytic adenoviruses) have been developed to overcome the physical and immunological barriers of solid tumors.

Schematic diagram of the cancer-selective killing efficacy of oncolytic adenovirus.

Figure 1. Schematic diagram of the cancer-selective killing efficacy of oncolytic adenovirus.

For years of experience in immunology and oncology, QVirus™ platform can provide oncolytic virus development service for clients around the world. We have the tools to construct your recombinant oncolytic adenoviruses easily and at low cost.

The Features of Our Oncolytic Adenovirus Service

  • Oncolytic adenovirus vectors with the E1 region under the control of a tumor-specific promoter
  • Oncolytic adenovirus vectors with the E1 region under the control of a tumor-specific promoter and with a transgene expressed in the E3 region ("Armed" oncolytic vectors)
  • E3 region: WT, or deleted (1.6 or 2.7 kb) with multiple cloning site
  • E4 region: WT, or deleted (1.2 or 2.8 kb)
  • Oncolytic adenovirus can be armed with genes that increase viral replication or progeny release to enhance virus replication
  • Therapeutic oncolytic adenovirus vector design for host immune evasion
  • Oncolytic adenovirus vector design for immuno-oncolytic therapies

Oncolytic adenoviruses provide a promising platform for cancer-immunotherapy agents. Since the adenoviral structure and gene function have been well characterized, oncolytic adenoviruses can be easily modified and adapted to increase the selectivity and potency of vector transduction and replication in cancer cells. QVirus™ platform commits to developing efficacious oncolytic adenovirus for customer and enabling wider applications of adenovirus in oncolytic virotherapy of cancers. Please feel free to contact us for more information and quotation.

1. Alexander B, et al. Designer Oncolytic Adenovirus: Coming of Age. Cancers, 2018, 10(6):201-.
2. Ramon A. Oncolytic Adenoviruses in Cancer Treatment. Biomedicines, 2014, 2(1):36-49.
3. Niemann J, Kühnel, Florian. Oncolytic viruses: adenoviruses. Virus Genes, 2017.
4. Hanni U K, et al. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. Viruses, 2015, 7(11):6009-6042.
5. Choi I K, Yun C O . Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Therapy, 2013, 20(2):70-76.

Quick Inquiry

Our Platform / Application / Support / About Us / Contact Us

Copyright © 2007 - Creative Biogene. All Rights Reserved.

  • 45-1 Ramsey Road, Shirley, NY 11967, USA
  • Tel: 1-631-626-9181
  • Fax: 1-631-614-7828
  • Email: